Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement.
The post Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health appeared first on MedCity News.
